Your browser doesn't support javascript.
loading
Alzheimer's disease associated with Down syndrome: a genetic form of dementia.
Fortea, Juan; Zaman, Shahid H; Hartley, Sigan; Rafii, Michael S; Head, Elizabeth; Carmona-Iragui, Maria.
Affiliation
  • Fortea J; Sant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu y Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain; Barcelona Down Medical Center, Fundació Catalana Síndrome de Down, Barcelona, Spain; Centro de Investigación Biomédica en
  • Zaman SH; Department of Psychiatry, School of Clinical Medicine, University of Cambridge, Cambridge, UK; Cambridgeshire & Peterborough NHS Foundation Trust, Cambridge, UK.
  • Hartley S; Waisman Center, University of Wisconsin-Madison, Madison, WI, USA.
  • Rafii MS; Alzheimer's Therapeutic Research Institute (ATRI), Keck School of Medicine, University of Southern California, San Diego, CA, USA.
  • Head E; Department of Pathology and Laboratory Medicine, University of California, Irvine, CA, USA.
  • Carmona-Iragui M; Sant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu y Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain; Barcelona Down Medical Center, Fundació Catalana Síndrome de Down, Barcelona, Spain; Centro de Investigación Biomédica en
Lancet Neurol ; 20(11): 930-942, 2021 11.
Article in En | MEDLINE | ID: mdl-34687637
Adults with Down syndrome develop the neuropathological hallmarks of Alzheimer's disease and are at very high risk of developing early-onset dementia, which is now the leading cause of death in this population. Diagnosis of dementia remains a clinical challenge because of the lack of validated diagnostic criteria in this population, and because symptoms are overshadowed by the intellectual disability associated with Down syndrome. In people with Down syndrome, fluid and imaging biomarkers have shown good diagnostic performances and a strikingly similar temporality of changes with respect to sporadic and autosomal dominant Alzheimer's disease. Most importantly, there are no treatments to prevent Alzheimer's disease, even though adults with Down syndrome could be an optimal population in whom to conduct Alzheimer's disease prevention trials. Unprecedented research activity in Down syndrome is rapidly changing this bleak scenario that will translate into disease-modifying therapies that could benefit other populations.
Subject(s)

Full text: 1 Collection: 01-internacional Health context: 6_ODS3_enfermedades_notrasmisibles Database: MEDLINE Main subject: Down Syndrome / Alzheimer Disease / Intellectual Disability Type of study: Diagnostic_studies / Risk_factors_studies Limits: Adult / Humans Language: En Journal: Lancet Neurol Year: 2021 Document type: Article

Full text: 1 Collection: 01-internacional Health context: 6_ODS3_enfermedades_notrasmisibles Database: MEDLINE Main subject: Down Syndrome / Alzheimer Disease / Intellectual Disability Type of study: Diagnostic_studies / Risk_factors_studies Limits: Adult / Humans Language: En Journal: Lancet Neurol Year: 2021 Document type: Article